

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Mayne Pharma Group Limited</b>
<b>ABN</b>	<b>76 115 832 963</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Scott Anthony Richards
<b>Date of last notice</b>	2 August 2021

#### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Solium Nominees (Australia) Pty Ltd <Bare Allocated A/C> as nominee for Scott Richards (1) HSBC Nominees (Australia) Limited as nominee for Scott Anthony Richards (2) HSBC Nominees (Australia) Limited as nominee for Scott Anthony Richards & Susan Marie Richards <Northumberland Trust> (3)
<b>Date of change</b>	3 Dec 2021
<b>No. of securities held prior to change</b>	26,627,692 Ordinary Shares pursuant to Executive Share Loan Scheme (1) 3,862,906 Ordinary Shares (2) 1,722,463 Ordinary Shares (3) 3,681,297 Performance Rights pursuant to Performance Right and Option Plan
<b>Class</b>	Performance Rights
<b>Number acquired</b>	6,060,606
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Performance Rights - Nil

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

---

<b>No. of securities held after change</b>	26,627,692 Ordinary Shares pursuant to Executive Share Loan Scheme (1) 3,862,906 Ordinary Shares (2) 1,722,463 Ordinary Shares (3) 9,741,903 Performance Rights pursuant to Performance Right and Option Plan
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of performance rights pursuant to Resolution 6 in the Notice of Meeting for the Company's 2021 Annual General Meeting.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/a
<b>If prior written clearance was provided, on what date was this provided?</b>	N/a

---

<sup>+</sup> See chapter 19 for defined terms.